​

Benitec Biopharma (BNTC) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BNTC Stock Forecast

Benitec Biopharma (BNTC) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $29.00, with a high of $29.00 and a low of $29.00. This represents a 79.34% increase from the last price of $16.17.

- $6 $12 $18 $24 $30 High: $29 Avg: $29 Low: $29 Last Closed Price: $16.17

BNTC Stock Rating

Benitec Biopharma stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (83.33%), 1 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 1 5 0 Strong Sell Sell Hold Buy Strong Buy

BNTC Price Target Upside V Benchmarks

TypeNameUpside
StockBenitec Biopharma79.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$29.00$29.00
Last Closing Price$16.17$16.17$16.17
Upside/Downside-79.34%79.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2535---8
Sep, 2535---8
Aug, 2535---8
Jul, 2534---7
Jun, 2534---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2025Andreas ArgyridesOppenheimer$29.00$13.66112.30%79.34%
Oct 14, 2024Silvan TuerkcanJMP Securities$18.00$10.8665.75%11.32%
Oct 14, 2024Silvan TuerkcanJMP Securities$16.00$10.8647.33%-1.05%
Oct 14, 2024Mani ForooharLeerink Partners$13.00$10.8619.71%-19.60%
Sep 24, 2024Yasmeen RahimiPiper Sandler$30.00$8.88237.84%85.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2025OppenheimerOutperformOutperformhold
Nov 15, 2024Piper SandlerOverweightOverweighthold
Oct 18, 2024Piper SandlerOverweightOverweighthold
Oct 15, 2024OppenheimerOutperforminitialise
Oct 14, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Oct 14, 2024JMP SecuritiesOutperformOutperformhold
Oct 14, 2024Leerink PartnersOutperformOutperformhold
Sep 24, 2024Piper SandlerOverweightOverweighthold
Sep 12, 2024GuggenheimBuyinitialise
Jun 13, 2024Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-80 $-62 $-44 $-26 $-8 $10 Jun 21 Jun 22 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$-27.27$-19.31$-2.68$-1.05----
Avg Forecast$-77.94$-46.70$-7.17$-4.57$-6.67$-7.54$-5.83$5.86
High Forecast$-77.94$-46.70$-5.96$-1.68$-1.63$-2.41$-5.83$5.86
Low Forecast$-77.94$-46.70$-8.38$-11.75$-15.07$-19.97$-5.83$5.86
Surprise %-65.01%-58.65%-62.62%-77.02%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Jun 21 Jun 22 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$59.00K$73.00K$216.00K-----
Avg Forecast$146.61K$145.35K$149.71K$1.12M$320.56K$95.81M$45.01M$145.19M
High Forecast$146.61K$145.35K$149.71K$1.12M$320.56K$95.81M$45.01M$145.19M
Low Forecast$146.61K$145.35K$149.71K$1.12M$320.56K$95.81M$45.01M$145.19M
Surprise %-59.76%-49.78%44.28%-----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Jun 21 Jun 22 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$-13.88M$-18.21M$-21.75M$-37.92M----
Avg Forecast$-316.47M$-189.62M$-29.12M$-31.81M$-42.73M$-61.20M$-23.66M$23.79M
High Forecast$-316.47M$-189.62M$-24.19M$-6.84M$-6.63M$-9.79M$-23.66M$23.79M
Low Forecast$-316.47M$-189.62M$-34.04M$-47.70M$-61.19M$-81.09M$-23.66M$23.79M
Surprise %-95.61%-90.40%-25.30%19.18%----

BNTC Forecast FAQ

Is Benitec Biopharma stock a buy?

Benitec Biopharma stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Benitec Biopharma is a favorable investment for most analysts.

What is Benitec Biopharma's price target?

Benitec Biopharma's price target, set by 6 Wall Street analysts, averages $29 over the next 12 months. The price target range spans from $29 at the low end to $29 at the high end, suggesting a potential 79.34% change from the previous closing price of $16.17.

How does Benitec Biopharma stock forecast compare to its benchmarks?

Benitec Biopharma's stock forecast shows a 79.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Benitec Biopharma over the past three months?

  • October 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Benitec Biopharma’s EPS forecast?

Benitec Biopharma's average annual EPS forecast for its fiscal year ending in June 2026 is $-6.67, marking a 535.24% increase from the reported $-1.05 in 2025. Estimates for the following years are $-7.54 in 2027, $-5.83 in 2028, and $5.86 in 2029.

What is Benitec Biopharma’s revenue forecast?

Benitec Biopharma's average annual revenue forecast for its fiscal year ending in June 2026 is $320.56K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $95.81M, followed by $45.01M for 2028, and $145.19M for 2029.

What is Benitec Biopharma’s net income forecast?

Benitec Biopharma's net income forecast for the fiscal year ending in June 2026 stands at $-42.732M, representing an 12.70% increase from the reported $-37.917M in 2025. Projections indicate $-61.204M in 2027, $-23.66M in 2028, and $23.79M in 2029.